Introduction
Malaria caused by Plasmodium falciparum infection continues to be a leading cause of morbidity and mortality in children in sub-Saharan Africa [1] . Following repeated infections, non-sterile immunity develops that protects against more severe forms of the disease [2] . This type of semi-immunity is directed against the asexual blood-stage of the parasite. Passive transfer experiments have shown that antibodies play an important role in this immunity, by inhibiting excessive parasite replication [3, 4] . In principle, all stages of parasite development within the human body are potential vaccine targets: the pre-erythrocytic-stage, (parasites inoculated by infected mosquitoes, circulate briefly and then develop in liver cells); the asexual blood-stage, which causes disease symptoms and complications; and the sexualstages, when parasites differentiate into male and female gametes. The RTS,S vaccine, the first malaria vaccine to be evaluated in a phase 3 trial, elicits immunity against preerythrocytic stages and has shown consistent protection in clinical trials [5, 6] . The final results of the RTS,S phase 3 trial are an important landmark, but protective efficacy was moderate, and waned [7] . A number of approaches are being pursued to develop improved, second generation vaccines. These include asexual blood-stage vaccines, which seek to limit but not prevent parasitaemia. However, blood stage candidates that have been evaluated in clinical trials have shown no protection [8, 9] or protection limited to the vaccine parasite strain [10, 11] . Identifying the protective epitopes, and the variability in the antigens that are exposed to the immune system have posed major problems in the development of malaria vaccine candidates [12] . These challenges have led to the proposal that for a next generation malaria vaccine RTS,S should be complemented with conserved antigens from the bloodstage [13] . Some evidence of protection against blood-stage infection was seen in post-hoc 6 analyses of a phase 1 trial with a conserved part of the Merozoite Surface Protein 3 (MSP3) in Burkina Faso, suggesting a MSP3 vaccine might be effective [14] .
The recombinant fusion protein, GMZ2, contains conserved fragments of two P. falciparum asexual blood-stage antigens, Glutamate-Rich Protein (GLURP) and MSP3 [15] , both of which have been identified as targets of naturally acquired malaria immunity [16, 17] and specific IgG antibodies that are broadly inhibitory [18, 19] . Phase I clinical trials have shown good tolerability, safety and immunogenicity of GMZ2 adjuvanted with aluminum hydroxide (Alum) in malaria-naïve adults [20] as well as in African adults and children [21, 22] .
Functional anti-GMZ2 antibodies at levels comparable to those observed in naturally exposed individuals were generated [19] , but vaccine efficacy (VE) under natural exposure has not been evaluated.
Here, we report the first results of a multicenter phase 2 clinical trial to assess GMZ2/Alum vaccine efficacy in African children from Western, Central and East Africa.
Materials and methods

Study Populations
The trial was conducted in five sites with different transmission patterns. In Banfora and Sapone, Burkina Faso [23] and in Navrongo, Ghana, malaria transmission is intense and highly seasonal. In Iganga, Uganda [24] , and Lambaréné, Gabon, transmission occurs throughout the year. Cohort studies were performed before the trial to assess the incidence of malaria. Additional details about the sites are provided in the Protocol (supplementary materials).
Study design and ethics
This was a randomized, controlled, multicenter, double blind phase 2 trial to measure VE of GMZ2/alum in African children. Participants were allocated in a 1:1 ratio to receive three doses of either GMZ2/Alum or the control vaccine (rabies, Verorab) four weeks apart, and were followed for six months. The study was performed in accordance with the protocol (Supplement), the International Conference on Harmonization, the Declaration of Helsinki in its 5 th revision, and national regulatory requirements. The ethics committee and the regulatory authority of each country reviewed and approved the study (Supplement). An independent Data and Safety Monitoring Board reviewed the safety data (serious adverse events) during the trial. This trial is registered with PACTR, registration number: PACTR2010060002033537.
Study participants
Study participants were healthy children, aged 12-60 months, residing in the study areas and available for follow-up. They were not anemic (Hb<7g/dL) or malnourished (weight for age z-score <-2 --3), and did not have signs of a chronic illness or renal or hepatic abnormality.
They had not taken immunosuppressive medication, immunoglobulin or blood products in the last three months, or another investigational drug or vaccine in the last month, and had no history of hypersensitivity to vaccines and no history of splenectomy. Routine vaccinations were given outside a 14 days interval before and after a dose of study vaccine. Written informed consent was obtained from the parents or legal guardian of each participant, signed by an impartial witness if they could not read. Families of participants were asked to report to the clinical team whenever a study-child was unwell. Blood samples were taken for microscopy at the health facilities from children with fever or history of fever. All disease episodes were treated according to national or international guidelines. Registered artemisinin combination therapies were used for treatment of uncomplicated malaria. Parenteral artesunate or quinine was used to treat severe malaria according to national guidelines.
Randomization and masking
Randomization at each site was done in randomly permuted blocks of 10 generated using Stata version 10. Children were screened and those who met eligibility criteria were assigned a randomization envelope in numerical sequence. Children were randomized to receive either 100 μg GMZ2 (Novasep, Belgium), reconstituted in 0.5 ml adjuvant (Alum, Statens Serum Institut, Denmark) or rabies vaccine (Verorab, Sanofi Pasteur). All vaccine doses were given as intramuscular injections into the deltoid muscle, alternately in the left and right arms.
Syringes were masked and the vaccinating nurse was not involved in any other activity in the trial. Safety was assessed after the first 40 children were vaccinated at each site before continuing recruitment.
Outcomes
The primary endpoint was clinical malaria for 6-month after the first vaccination. Malaria was defined as asexual P. falciparum parasitemia of ≥5,000 parasites/μl with fever (tympanic temperature ≥38°C) or a history of fever in the previous 48 hours. Secondary endpoints included malaria with fever or history of fever and a parasite density >0, ≥500, ≥2,500, or ≥20,000/uL; incidence of solicited local and general symptoms within seven days of vaccination and unsolicited adverse events at any time; anemia (Hb<7g/dL) at six months;
and severe malaria, defined as hospitalization for at least 24 hours with malaria as primary diagnosis. Passive follow-up was used to capture malaria episodes.
To assess safety, participants were directly observed for 30 minutes after each vaccine injection, followed by daily home visits for six days. On Day 7, a physician examined participants at the clinic. Following the third vaccine injection, monthly home visits were done to check that the child was still present in the study area and to capture adverse events (AE) and serious AEs (SAE) that were not actively reported to the clinical team.
Laboratory methods
Five ml of blood was collected by venipuncture into EDTA tubes for hematology and into dry tube for biochemistry. Hemoglobin was determined using a Hemocue analyzer at all sites.
Full blood counts and biochemistry were done using calibrated automatic analyzers. P.
falciparum parasitemia was assessed using two independent reads of Giemsa-stained thick blood smears at a 1000x magnification, followed by a third read in case of discordance (disagreement on positivity or a >2-fold difference in parasitemia). The number of parasites per µl of blood was calculated according to the measured leucocyte count. A slide was declared negative if no parasite was seen after microscopic examination of 200 high power fields. GMZ2-specific IgG antibody levels were determined by ELISA as previously described in detail using the vaccine antigen preparation for capture of antibodies [21] .
Antibody concentrations are given as titers normalized to a highly positive pool. A titer of one would mean the same anti-GMZ2 antibody concentration as in the pool, 0.1 a 10-fold lower concentration.
Statistical methods
Sample size was calculated to have at least 90% power for the According to Protocol (ATP)
analysis if the VE was at least 30%, using a 5% significance level, allowing for 15% loss to follow-up or incomplete vaccination. All children who were randomized were included in the Intention to Treat (ITT) analysis, those who received three doses of either GMZ2 or rabies vaccine were included in the ATP analysis. Time at risk was calculated from randomization (ITT) or from the date of the third dose of vaccine (ATP), until six months after the date for the third dose. VE, defined as the percentage reduction in the number of malaria episodes, was calculated as 100x(1-R), where R is the hazard ratio estimated by Cox regression, with site as a stratification factor, and confidence interval calculated using a robust standard error to account for repeated episodes in the same child. Cases that occurred within 14 days of a previous episode were not counted. A Statistical Analysis Plan (Supplement) was prepared before database lock and unblinding. Subgroup analyses by site, age group and use of insecticide-treated nets (ITN) was planned. Completed paper case record forms were quality checked and transcribed into a database using eClinical eDM and eDC system version 5.0.
Single data entry was used, with verification of the data entry by proof reading of selected areas combined with full proof reading of selected CRFs to verify accuracy.
Results
Participants
Between November 2010 and September 2011, 1849 children were enrolled ( Figure 1 , and Supplementary Figure S1 ). Demographics and other baseline characteristics were similar in the two groups although there was a slightly higher proportion of older children in the rabies vaccine group (Table 1 and supplementary Table S1 ).
Efficacy
During the six-month follow up, there were 1361 episodes of malaria with parasite density of ≥5000 parasites per μL amongst those who received three doses of vaccine, 641 in the GMZ2/Alum group and 720 in the control group (Fig. 2 ). In the per-protocol analysis, VE, adjusted for age and site, was 13.6% (95% confidence interval [CI] 3.6%,23%, pvalue=0.009). In the ITT analysis, there were 1925 episodes of malaria with parasite density of ≥5000 parasites per μL, 920 in the GMZ2/Alum group and 1005 in the control group with age-adjusted VE of 11.3% (95% CI 2.5%,19%, p-value=0.013). Similar estimates were obtained when different parasite density cut-offs were used (Table 2) . Similar estimates were also obtained when age was not included in the model (Table 2 ). There was no evidence that efficacy varied by site (Supplementary Table S2 ). The number of children with one or more episodes of malaria is listed in supplementary Table S3 . VE (ATP), adjusted for age and site, from the Kaplan Meier estimates of the proportion with malaria was 7.63% (95% CI, 0.95%,13.86%) and 6.36% (95% CI, 1.53 %,10.95%) in the ITT analysis. VE (ATP) was 20% (4%,33%) in children 3-4yrs of age and 6% (-8%,18%) in children 1-2yrs of age, interaction P-value 0.112. In the ITT analysis the VE was 18% (5%, 30%) in children 3-4yrs of age and 3% (-10%, 14%) in children 1-2yrs of age, interaction p-value=0.057. The proportion of children with fever, at a given parasite density, was lower in the older agegroup than in younger children in both vaccine groups (odds ratio for fever adjusted for site 0.72 (95%CI 0.59,0.89) (supplementary Figure S2 ). The distribution of parasite density among cases treated for malaria was similar in the GMZ2/Alum and rabies vaccine groups (supplementary Figure S2 ).
Thirty-two cases of severe malaria were reported in children who had received three doses of vaccine, 18 in the rabies group and 14 in the GMZ2/Alum group. In the ATP analysis, VE against severe malaria adjusted for age and site was 27% (95%CI -44%,63%) while in the ITT analysis, VE was 20% (95% CI -41%,55%). The prevalence of anemia after 6-months follow-up was similar (OR=2.96, 95% CI 0.60-14.7, p=0.185) in the GMZ2/Alum group (6/816) and in the rabies vaccine group (2/793).
Safety and reactogenicity
Vaccine doses were well tolerated (supplementary Tables S4 -S6 ). There were 17 individuals in the rabies group and 29 in the GMZ2/Alum group with solicited, grade 3 AE within seven days of a dose. Of these, four in the rabies group (two induration and two fever Table S6 ). During the six months follow-up period post dose 3, five children died, two in the GMZ2/Alum group and three in the control group (Supplementary Table S7 ).
There were 68 other SAEs (35 in the rabies group and 33 in the GMZ2/Alum group) most of these were malaria (Supplementary Table S8 ). Two of the SAEs were considered related to vaccination, both events in one individual who had received rabies vaccine.
Immunogenicity
The mean titer of anti-GMZ2 antibodies increased 8-fold (95%CI 6.1,11) from baseline in children who received three doses of GMZ2/Alum. There was a greater increase in children 1-2yrs old (14-fold increase, 95% CI 8.7, 23) compared to children 3-4yrs old (5.7-fold, 95%
CI 4.0,8.2), however the smaller increase in older children was due to a higher baseline level of naturally acquired antibodies (Table 3) . At baseline, arithmetic mean GMZ2 IgG levels were 0.09 and 0.21 in the 1-2yrs and 3-4 yrs age groups, respectively (Table 3) . A similar effect of age was also observed in the rabies vaccine group (Table 3) . To investigate the association between the concentration of anti-GMZ2 IgG antibodies measured after the third vaccine dose (Day 84) and malaria incidence, children in the GMZ2/Alum group were divided into four groups based on the quartiles of the anti-GMZ2 antibody concentration (Table 4) . Children with anti-GMZ2 antibody concentrations above the upper quartile had 23% (95%CI 1.8%,39%; p-value=0.035) lower incidence of clinical malaria, compared with children in the lowest quartile group. This association remains after adjusting for age-related exposure to P. falciparum malaria.
Discussion
GMZ2/Alum was well tolerated and immunogenic in children from West, Central, and East Africa. Although efficacy is too low for the vaccine to have a role in public health in its present form, the finding that the risk of acquiring clinical malaria decreased with increasing levels of GMZ2-specific antibodies, suggests that efficacy might improve if immunogenicity can be enhanced with improved formulations or a more potent adjuvant. Preclinical studies in
Saimiri sciureus monkeys suggested that stronger adjuvants enhance both immunogenicity and protective efficacy of GMZ2 [25] . Whether novel formulations using stronger adjuvants may elicit significantly better protection against clinical disease remains to be investigated.
The worldwide dynamics of P. falciparum populations is complex and the distribution of different parasite strains differs from region to region and evolves over time possibly because of immune selection [26] . Multicenter trials in a range of different settings are therefore required to show that efficacy of vaccine candidates is not site dependent. We did not find evidence of variation in efficacy, although site effects cannot be ruled out, as the power for the interaction test was low. The limited antigenic variation observed in the GLURP and MSP3 regions included in the GMZ2 vaccine may facilitate the generation of broadly inhibitory antibodies as suggested in functional bioassays assay using geographically and genetically diverse P. falciparum isolates [18, 19] . These studies, together with a preclinical study using the GLURP component of GMZ2 [27] , suggests that GMZ2 may generated a broad anti-parasitic immune response that covers more than a small number of isolates. This is particularly important in areas of high endemicity, where infections are usually complex.
On the other hand, IgG antibodies against the components of GMZ2 may also control parasite multiplication through opsonic phagocytosis of P. falciparum merozoites [28] . Functional analyses of GMZ2 IgG from the present trial would be important to identify surrogate markers of protection [29] .
GMZ2/Alum elicits higher protection in children 3-4 years of age compared to children 1-2 years of age. The interaction with age may suggest that vaccine-induced antibodies act in concert with protective antibodies acquired through natural exposure [30] and/or are more functionally competent in terms of avidity and IgG subclass profile [31] . We did not find any evidence that efficacy waned during the six months of follow-up, however analysis of longer term follow up, which is planned, will be required to give a better estimate of duration of protection. Numerous immune-epidemiological studies have demonstrated an association between the level of antibodies against GLURP and MSP3 and protection from clinical malaria [16, 17, 32] . In this trial, we found a relationship between concentration of vaccineinduced antibodies and incidence of clinical malaria. Children in the GMZ2/Alum group with anti-GMZ2 IgG concentrations above the upper quartile had 23% fewer episodes of clinical malaria than children with in the lowest group This effect of high GMZ2 IgG antibodies was independent of age. In fact, there was an indication that children 1-2 yrs of age with low prevaccination GMZ2 IgG levels responded strongly to vaccination, whereas older children with more exposure to P. falciparum showed a smaller boost of GMZ2 IgG responses. This is in accordance with our previous findings [20] [21] [22] and suggests that prior exposure to P.
falciparum might diminish subsequent boosting by vaccination. Together, these observations suggest that an increased immunogenicity of GMZ2 may improve VE. The present vaccine formulation is based on Alum which is not as potent as more recently developed adjuvants.
Notably, a formulation of RTS,S with Alum was not efficacious [33] . New formulations such as oil-in-water emulsions [34] [35] [36] may improve immunogenicity and efficacy of GMZ2.
Efficacy of the RTS,S vaccine against severe disease appeared to be limited by rebound effects that occurred due to delayed acquisition of natural immunity [7] . Blood-stage vaccines might be less likely than pre-erythrocytic vaccines to interfere with acquisition of natural immunity as they do not prevent infection but this would need to be evaluated in larger trials.
The safety and reactogenicity profile of GMZ2/Alum was good, consistent with previous clinical trials [20] [21] [22] . GMZ2 could be combined with other vaccines to improve protection [2]
Druilhe P, Perignon JL. Mechanisms of defense against P. falciparum asexual blood stages in humans. ImmunolLett 1994 1994;41(2-3):115-20.
[3]
McGregor IA, Carrington SP, Cohen S. Treatment of East African P. falciparum malaria with West African gammaglobulin. TransRSocTropMedHyg 1963 TransRSocTropMedHyg 1963 57:170-5. [4] Cohen S, McGregor A, Carrington S. Gamma globulin and aquired immunity to human malaria. Nature 1961 Nature 1961 192:733-7 . [31] Bouharoun-Tayoun H, Druilhe P. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. InfectImmun 1992 1992;60:1473-81. respectively were seen at the scheduled 6 month visit. There were three allocation errors: one child randomized to receive rabies vaccine was given three doses of GMZ2, (this child was included in per-protocol analysis); two children, one randomized to rabies vaccine and the other to GMZ2, received mixed doses, these children were excluded from the per-protocol analysis but were included in ITT analysis. Figure 2S . The probability of fever in the rabies vaccine (in blue) and GMZ2 group (in red) in relation to parasite density, in each age group in each site. Smoothed plots of the probability of fever were obtained using fractional polynomial logistic regression.
Supplementary
Dashed lines show 90% confidence limits. The arrow shows the density associated with a 50% probability of fever to facilitate comparison between the plots. There is no density corresponding to 50% probability of fever in Saphone. The distribution of parasite densities in the rabies vaccine group in each site and age group is shown as a histogram. Table 4 : Association between GMZ2 IgG titre measured on day 84, and the incidence of malaria in each vaccine group.
GMZ2
Rabies vaccine were included in the per-protocol analysis. 809/867 (%) and 827/868 (%) respectively were seen at the scheduled 6 month visit. There were three allocation errors: one child randomized to receive rabies vaccine was given three doses of GMZ2, (this child was included in per-protocol analysis); two children, one randomized to rabies vaccine and the other to GMZ2, received mixed doses, these children were excluded from the per-protocol analysis but were included in ITT analysis. Weight in kg (mean, 12.9 (6.9-95) 12.3 (7.6 -12.4 (7.6 -12.5 (7.4 -13.2 (7.4 -12.7 (7.5 -13.1 (6.2 -13.3 (7-41) 1 (23.3 -41.6 (1.1-41.5 (20 -42.4 (8 -31.0 (7-74) 31.6 (15-38.1 (22.9 -40.2 (19.9 -36.4 (18.4 -32.6 (0.5 - *Slept under a treated net the night before the survey. Note bednet use was not measured at baseline but after the 6 month visit. 
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Supplementary Figure 2S : The probability of fever in the rabies vaccine (in blue) and GMZ2 group (in red) in relation to parasite density, in each age group in each site.
Smoothed plots of the probability of fever were obtained using fractional polynomial logistic Uganda log 10 parasite density/ L associated with a 50% probability of fever to facilitate comparison between the plots. There is no density corresponding to 50% probability of fever in Saphone. The distribution of parasite densities in the rabies vaccine group in each site and age group is shown as a histogram.
